In cancer, genetic heterogeneity is the focus of many investigations as it plays important roles in tumor progression and drug resistance by driving phenotypic diversity. Here, we consider another type of heterogeneity, one where natural cell-to-cell variability in protein levels in genetically-identical mammalian cells causes the same stimuli to yield different cell fates, such as life or death. We term this phenomenon natural phenotypic divergence (NPD). NPD can manifest as, for example, a persistent anticancer drug resistant subpopulation of cells, and understanding it is important for predicting cancer treatment efficacy. However, means to predict NPD from cell-based experiments have not been developed and are the subject of the proposal. We hypothesize that NPD can be predicted by characterizing how multivariate, endogenous protein expression noise is propagated non-linearly through signaling networks to regulate cell fate. It is the endogenous expression and degradation noise in the levels of multiple proteins within a signaling network that collectively manifest as NPD. We will test this hypothesis by combining experimental and computational approaches to examine NPD-based proliferation of non-transformed MCF10A cells. This proliferation is induced by combinations of epidermal growth factor, insulin, and cortisol and mediated by activation of the ERK, Akt, JNK, and SGK pathways. First, experimentally, we will use live-cell imaging approaches with FRET probes to measure real-time signaling network dynamics and proliferation simultaneously. Although we can only measure one pathway at a time, our subsequent use of computational, dynamic modular response analysis theory allows us to reconstruct how these pathways dynamically interact in a stimulus-specific fashion to control stochastic proliferation fates. Second, we will build a chemical kinetics-based, stochastic computational model that simulates how the protein expression variability underlying NPD propagates into signaling dynamics heterogeneity. Analysis of this model will suggest sets of key proteins whose collective, multivariate fluctuations have a large influence on NPD-based proliferation. Finally, we will measure fluctuations in the levels of these key proteins in single ive cells, use our computational models to predict whether these cells should proliferate or not in response to defined perturbations, and test the predictions by observing the actual proliferation decision in those same cells. We will test such predictions not only in standard 2D cell culture models, but also in the context of 3D culture acini formation. If successful, this would be the firt demonstration that the stochastic fates of individual live cells could be predicted based on biomarkers present prior to perturbation. This would be an important step towards identifying biomarker sets for individual patients and fashioning personalized therapeutic strategies.

Public Health Relevance

Cancer cells within a tumor are typically very different from one another, and we cannot generally predict whether individual cells will be sensitive or resistant to treatment. This proposal entails a combination of experimental and mathematical modeling methods to understand how one might predict whether individual cells will proliferate or not in response to a treatment. The ability to predict stochastic fates of individual cells in response to treatment can help catalyze the improvement of current and the proposal of new cancer treatment strategies.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Biodata Management and Analysis Study Section (BDMA)
Program Officer
Resat, Haluk
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Clemson University
Engineering (All Types)
Biomed Engr/Col Engr/Engr Sta
United States
Zip Code
Jones, DeAnalisa C; Scanteianu, Adriana; DiStefano, Matthew et al. (2018) Analysis of copy number loss of the ErbB4 receptor tyrosine kinase in glioblastoma. PLoS One 13:e0190664
Barrette, Anne Marie; Bouhaddou, Mehdi; Birtwistle, Marc R (2018) Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials. ACS Chem Neurosci 9:118-129
Bouhaddou, Mehdi; Barrette, Anne Marie; Stern, Alan D et al. (2018) A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens. PLoS Comput Biol 14:e1005985
Koch, Rick J; Barrette, Anne Marie; Stern, Alan D et al. (2018) Validating Antibodies for Quantitative Western Blot Measurements with Microwestern Array. Sci Rep 8:11329
Xiong, Yuguang; Soumillon, Magali; Wu, Jie et al. (2017) A Comparison of mRNA Sequencing with Random Primed and 3'-Directed Libraries. Sci Rep 7:14626
Shim, Jaehee V; Chun, Bryan; van Hasselt, Johan G C et al. (2017) Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics. Front Physiol 8:651
Stern, Alan D; Rahman, Adeeb H; Birtwistle, Marc R (2017) Cell size assays for mass cytometry. Cytometry A 91:14-24
Byrne, Kate M; Monsefi, Naser; Dawson, John C et al. (2016) Bistability in the Rac1, PAK, and RhoA Signaling Network Drives Actin Cytoskeleton Dynamics and Cell Motility Switches. Cell Syst 2:38-48
Smith, Gregory R; Birtwistle, Marc R (2016) A Mechanistic Beta-Binomial Probability Model for mRNA Sequencing Data. PLoS One 11:e0157828
Farrelly, L A; Dill, B D; Molina, H et al. (2016) Current Proteomic Methods to Investigate the Dynamics of Histone Turnover in the Central Nervous System. Methods Enzymol 574:331-354

Showing the most recent 10 out of 18 publications